Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603)

Authors :: A. Sugama
Shota Fukuoka
Yosuke Togashi
Hiroki Hara
Takashi Kojima
Masashi Wakabayashi
A. Sato
Hiroyoshi Nishikawa
Naoki Takahashi
H. Tamura
Daisuke Kotani
Y. Mikamoto
K. Shitara
Akihito Kawazoe
Takako Yoshii
Sachiyo Nomura
Masako Asayama
Source :: Annals of Oncology. 30:iv124
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Cancer
Hematology
Expansion phase
medicine.disease
Dose finding
chemistry.chemical_compound
chemistry
Internal medicine
Regorafenib
Medicine
In patient
Nivolumab
Open label
business

Full Text Access

Tools